Hisamitsu Pharmaceutical Co.,Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hisamitsu Pharmaceutical Co.,Inc.
Also, two more health care-focused SPACs went public, Centessa obtained up to $300m in debt, three new venture capital funds launched and Intergalactic debuted with a $75m series A round.
With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.
ProQR’s Axiomer platform can enable single nucleotide RNA editing, an approach that could address thousands of disease-causing genetic mutations, the company says.
Hisamitsu America launches online portal exclusively for health care professionals. Also in OTC topical space, Beutlich Pharmaceuticals extends HurriCaine benzocaine gel and spray line with oral anesthetic single-dose packages in five flavors.
- Medical Devices
- Drug Delivery
- OTC, Consumer
- Other Names / Subsidiaries
- CRCC Media Co.,Ltd. (Fukuoka)
- Saga City-Vision Co.,Ltd. (Saga)
- Taiyo Co.,Ltd (Saga)
- Kyudo Co.,Ltd (Saga)
- Hisamitsu Agency Co.,Ltd. (Fukuoka)
- Hisamitsu U.S., Inc.
- Hisamitsu America, Inc.
- Noven Pharmaceuticals, Inc.
- Hisamitsu Farmaceutica do Brasil Ltda.
- Hisamitsu UK Ltd.
- Hisamitsu Italia S.r.l.
- Hisamitsu Vietnam Pharmaceutical Co.,Ltd.
- Hisamitsu Pharmaceutical(China)Co.,Ltd.
- Hisamitsu Pharmaceutical Technology Consulting(Beijing) Co.,Ltd.
- Hisamitsu Pharmaceutical (Hong Kong)Co.,Ltd.
- PT. Hisamitsu Pharma Indonesia